Molecular profiling in HNSCC patients targets potential responsiveness to ICIs

Abstract Immunotherapy is emerging as a valid therapeutic strategy for various cancers although only a subset of patients responding to the therapy. The response to immunotherapy remains low for many cancer types because of poor ability to appropriately classify responding patients.